Abstract:Abstract Background Glucocorticoids are frequently used as a primary chemotherapeutic agent in many types of human lymphoid malignancies because they induce apoptosis through activation of the glucocorticoid receptor, with subsequent alteration of a complex network of cellular mechanisms. Despite clinical usage for over fifty years, the complete mechanism responsible for glucocorticoid-related apoptosis or resistance remains elusive. The mitogen-activated protein kinase pathway is a signal transduction network that influences a variety of cellular responses through phosphorylation of specific target substrates, including the glucocorticoid receptor. In this study we have evaluated the pharmaceutical scenarios which converge on the mitogen-activated protein kinase pathway to alter glucocorticoid sensitivity in clones of human acute lymphoblastic CEM cells sensitive and refractory to apoptosis in response to the synthetic glucocorticoid dexamethasone. Results The glucocorticoid-resistant clone CEM-C1-15 displays a combination of high constitutive JNK activity and dexamethasone-induced ERK activity with a weak induction of p38 upon glucocorticoid treatment. The cells become sensitive to glucocorticoid-evoked apoptosis after: (1) inhibition of JNK and ERK activity, (2) stimulation of the cAMP/PKA pathway with forskolin, or (3) inhibition of mTOR with rapamycin. Treatments 1–3 in combination with dexamethasone alter the intracellular balance of phospho-MAPKs by lowering JNK phosphorylation and increasing the level of glucocorticoid receptor phosphorylated at serine 211, a modification known to enhance receptor activity. Conclusion Our data support the hypothesis that mitogen-activated protein kinases influence the ability of certain malignant lymphoid cells to undergo apoptosis when treated with glucocorticoid. Activated/phosphorylated JNK and ERK appear to counteract corticoid-dependent apoptosis. Inhibiting these MAPKs restores corticoid sensitivity to a resistant clone of CEM cells. Forskolin, which activates the cAMP pathway, and rapamycin, which inhibits mTOR, also inhibit JNK. Further, the sensitizing treatments result in a largely dexamethasone-dependent increase in the total pool of glucocorticoid receptor phosphorylated at serine 211. The phospho-serine 211 receptor is known to be more potent in activating gene transcription and apoptosis. The interactive effects demonstrated here in reverting resistant cells to corticoid sensitivity could provide therapeutic clinical potential in the treatment of lymphoid malignancies.

Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma

Rapamycin Sensitizes T-ALL Cells to Dexamethasone-Induced Apoptosis

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G 1 cell cycle arrest and apoptosis

Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis

Rapamycin Sensitizes Glucocorticoid Resistant Acute Lymphoblastic Leukemia Cem-C1 Cells to Dexamethasone Induced Apoptosis Through Both Mtor Suppression and Up-Regulation and Activation of Glucocorticoid Receptor

Rapamycin Reverses Glucocorticoid Resistance in Human T-cell Acute Lymphoblastic Leukemia CEM-C1 Cells

Synergistic Effect of Targeting Mtor by Rapamycin and Depleting ATP by Inhibition of Glycolysis in Lymphoma and Leukemia Cells

Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells

In Vitro Study of the Effect of Cyclosporine A, Tetrandrine and Their Combination on the Reversion of Multidrug Resistance in Leukemia Cell Line.

Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‐S6k pathway

Glucocorticoid Resistance in Acute Lymphoblastic Leukemia:Molecular Mechanisms and Related Issues

Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.

Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity

Inhibition of Mtorc1 Signaling Sensitizes Hepatocellular Carcinoma Cells to Glycolytic Stress

mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells

CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer Through Abrogating Mtor Inhibition-Induced Phosphorylation of Eif4e and Activating Mitochondrial Apoptotic Pathway.

Berberine Sensitizes Rapamycin-Mediated Human Hepatoma Cell Death in Vitro

Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells

The Enhancement of Radio-Sensitivity Via Autophagy Induced by Rapamycin with Glioma-Initiating Cells in Vivo